SNY is waiting for FDA approval on oxaliplatin for colorectal CA. A recent preliminary report from the NCI showed a 4-month survival advantage for a regimen containing oxaliplatin compared to a regimen that contained Pharmacia's Camptosar. The SNY compound was also better tolerated. It was placed on FDA fast-track status and could be cleared for marketing within the next few weeks. Rumor has it that Sanofi is also going out and hiring an experienced oncology sales force to market their products. I don't know much about the rest of their products, but I like the looks of their cancer portfolio. BHR
Oxaliplatin will be huge! Everyone has been waiting for it. SHould have been out 2 years ago but try and tell the French how to conduct clinical trials! As far as the rumors of a onc. sales force I can't confirm this. Pharmacia rep told me that he had heard it but can't confirm either! Maybe they will hire Bristol to market it. Oringially it was going to be Lilly but they backed out! My biggest concern about the French is their ability to market! They get a little cocky at times and tend to be tight wads! Knowing the French they will hire college grads at 25,000 a year after it has been out for a year to try and gain a little more market share! Maybe they got it down to a fine science by hiring long legged bunnies!
I can confirm that Sanofi is buying an experienced oncology sales force. I personally know 2 people they have hired in the last week, both of whom have 5+ years in oncology sales. I also understand there are a lot of experienced Immunex reps available since the merger with Amgen. An experienced sales force marketing oxaliplatin should be exciting.